• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Indivior touts late-stage trial for monthly buprenorphine depot

June 22, 2017 By Sarah Faulkner

IndiviorIndivior (LON:INDV) touted data today from its pivotal Phase III trial for RBP-6000, a once-monthly injectable buprenorphine depot for the treatment of adults with opioid use disorder.

The 24-week study met its primary and key secondary endpoints for both dosage regimens, according to the company.

“The clinical data from our Phase III study also showed that outcomes with RBP-6000 are consistent across other secondary clinical endpoints, including control of craving and withdrawal symptoms, as compared to placebo,” chief scientific officer Christian Heidbreder said in prepared remarks. “These outcomes started with the first dose of RBP-6000, which achieved buprenorphine plasma concentrations ≥ 2 ng/mL and predicted whole brain mu-opioid receptor occupancy of ≥ 70%, and were also maintained for the one-month dosing intervals and for the entire treatment duration.”

The trial enrolled 504 treatment-seeking adults, ages 19 to 64, with moderate or severe opioid use disorder who were not receiving medication-assisted treatment. The patients were randomized to receive either 1 of 2 dosage regimens of RBP-6000 or palcebo.

Prior to randomization, all study participants were inducted and stabilized with a sublingual film of Suboxone (buprenorphine and naloxone) to ensure that they weren’t allergic to buprenorphine and to suppress opioid withdrawal signs, Indivior said.

The participants were randomized to receive 6 once-monthly 300 milligram doses, 2 once-monthly 300 milligram doses followed by 4 once-monthly 100 milligram doses or 6 once-monthly subcutaneous placebo injections. The study subjects also received manual-guided psychosocial support at least once a week.

The primary efficacy endpoint was the mean percentage abstinence, or weeks spent opioid-free, combined with self-reports negative for illicit opioid use from week 5 to week 24. The key secondary endpoint was treatment success, defined as any participant with greater than or equal to 80% of urine samples negative for opioids.

RBP-6000 met the primary efficacy endpoint and both dosage regimens yielded significantly higher abstinence rates compared to the placebo. Both dosages also met the key secondary endpoint of treatment success, Indivior reported.

The depot was generally well tolerated in the late-stage trial, as 2.7% of subjects on both dosage regimens combined experienced a serious treatment-emergent adverse event compared to 5% of participants on placebo.

Also, approximately 60% of patients in each dosage group finished the study versus 33.3% of the people taking a placebo.

“Opioid use disorder is a chronic, relapsing medical condition with multiple factors playing a role and impacting  patient outcomes, including control of withdrawal symptoms, cravings and relapse to illicit opioid use,” principal investigator Dr. Amit Vijapura said. “If approved, RBP-6000 could help address the unmet needs of patients and represent a potentially important new option for the treatment of opioid use disorder.”

Indivior submitted a new drug application to the FDA last month, looking for marketing approval for RBP-6000 as a treatment for adults with moderate-to-severe opioid use disorder in combination with counseling and psychosocial support.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Clinical Trials, Featured, Pain Management, Pharmaceuticals Tagged With: indivior

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS